Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

深圳市海普瑞药业集团股份有限公司 is a multinational pharmaceutical company focused on providing high-quality, safe, and effective medications and services to patients around the world, driven by unmet clinical needs.

深圳市海普瑞药业集团股份有限公司

Hepalink Group | 556 followers on LinkedIn. Discover, develop, and commercialize high-quality, safe and effective medicines and services to address patients’ unmet  | Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs.

These three synergistic business segments are driven by the mission of addressing patients’ unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Heparin Supply Chain / Global Supply Chain Division at Shenzhen Hepalink Pharmaceutical Co., Ltd.

Danuta (Danka) Andersen

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue							4.62B -	5.33B 15.30%			5.42B -
cost of revenue							2.90B -	3.24B 11.90%			3.75B -
gross profit							1.73B -	2.09B 21.00%			1.68B -
selling and marketing expenses		13.03M -					411.32M -	408.90M 0.59%			517.42M -
general and administrative expenses							128.33M -	150.77M 17.48%		146.49M -	458.57M 213.03%
selling general and administrative expenses							539.65M -	559.67M 3.71%			906.83M -
research and development expenses							148.71M -	160.01M 7.59%			173.15M -
other expenses	4.58M -	7.00M 53.02%	47.22M 574.49%	40.00M 15.28%	11.91M 70.24%	9.70M 18.53%	208.14M 2,045.71%	241.30M 15.93%	274.94M 13.94%	294.71M 7.19%	-855.38M 390.24%
cost and expenses							3.80B -	4.21B 10.79%			5.68B -
operating expenses	224.77M -	324.28M 44.27%	398.71M 22.95%	457.11M 14.65%	450.61M 1.42%	845.39M 87.61%	896.50M 6.05%	960.98M 7.19%	1.07B 11.23%	1.21B 13.38%	1.94B 59.70%
interest expense							257.80M -	247.72M 3.91%			223.22M -
ebitda							1.95B -	1.96B 0.50%			124.72M -
operating income							1.31B -	1.33B 1.16%			-259.95M -
depreciation and amortization							638.23M -	632.77M 0.85%			384.67M -
total other income expenses net							202.38K -				-220.44M -
income before tax							1.31B -	1.33B 0.98%			-480.38M -
income tax expense							271.38M -	306.20M 12.83%			-126.17M -
net income	317.33M -	338.28M 6.60%	579.78M 71.39%	396.89M 31.54%	131.33M 66.91%	616.19M 369.19%	1.06B 71.92%	1.02B 3.32%	240.79M 76.49%	727.08M 201.96%	-783.26M 207.73%
weighted average shs out	1.28B -	1.28B 0.02%	1.27B 1.01%	1.25B 1.07%	1.25B 0.55%	1.25B 0.02%	1.25B 0.01%	1.35B 8.51%	1.47B 8.42%	1.47B 0.00%	1.47B 0.00%
weighted average shs out dil	1.28B -	1.28B 0.02%	1.27B 1.01%	1.25B 1.07%	1.25B 0.55%	1.25B 0.02%	1.25B 0.01%	1.35B 8.51%	1.47B 8.42%	1.47B 0.00%	1.47B 0.00%
eps	0.25 -	0.26 4.00%	0.46 76.92%	0.32 30.43%	0.16 50%	0.49 206.25%	0.85 73.47%	0.76 10.59%	0.16 78.95%	0.50 212.50%	-0.53 206%
epsdiluted	0.25 -	0.26 4.00%	0.46 76.92%	0.32 30.43%	0.16 50%	0.49 206.25%	0.85 73.47%	0.76 10.59%	0.16 78.95%	0.50 212.50%	-0.53 206%

0023

COM:HEPALINK

深圳市海普瑞药业集团股份有限公司

Last Close

11.38

22/11 07:04

Market Cap

11.43B

Beta: -

Volume Today

4.27M

Avg: -

Preview